Safe Harbor

Forward-looking statements

This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of Heidelberg Pharma AG. This material may not be distributed within countries where it may violate applicable law.
Heidelberg Pharma at a Glance

Developing new options to address major challenges in cancer therapy

Our Company
- Listed as Heidelberg Pharma AG
- Frankfurt Stock Exchange: WL6
- Shares outstanding: 28.16 million
- Market cap: ~€80 million
- Headquarters: Ladenburg, Germany
- 66 employees

Our Mission
- Improve efficacy
- Overcome resistance mechanisms
- Kill dormant tumor cells
- Provide new options in cancer therapy

Our Approach
- New mode of action in cancer therapy
  - Induction of apoptosis by inhibition of RNA Polymerase II
  - Application of innovative payload by harnessing ADC therapeutic modality
- Antibody Targeted Amanitin Conjugates (ATACs)
### ATACs – Growing Pipeline of Proprietary and Partnered Programs

<table>
<thead>
<tr>
<th>Product</th>
<th>Target</th>
<th>Indication</th>
<th>Research</th>
<th>Preclinic</th>
<th>Clinic</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proprietary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDP-101</td>
<td>BCMA</td>
<td>Multiple myeloma (DLBCL/CLL)</td>
<td></td>
<td></td>
<td>I</td>
<td>Proprietary</td>
</tr>
<tr>
<td>PSMA-ATAC</td>
<td>PSMA</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td>II</td>
<td>Proprietary</td>
</tr>
<tr>
<td>CD19-ATAC</td>
<td>CD19</td>
<td>Hematological tumors</td>
<td></td>
<td></td>
<td>III</td>
<td>Proprietary</td>
</tr>
<tr>
<td>XX-ATACs</td>
<td>n/a</td>
<td>Leukemias &amp; solid tumors</td>
<td></td>
<td>I</td>
<td></td>
<td>Undisclosed</td>
</tr>
<tr>
<td>ATAC technology partner</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TAK-XX-ATACs</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
<td>I</td>
<td></td>
<td>Takeda/ Millennium</td>
</tr>
<tr>
<td>MGTA-XX-ATACs</td>
<td>CD117, CD45</td>
<td>HSCs, Conditioning programs for bone marrow transplant in AML</td>
<td></td>
<td></td>
<td></td>
<td>Magenta</td>
</tr>
</tbody>
</table>
Recent Key Achievements

Proprietary ATAC Programs

Lead program, HDP-101
- GMP manufacturing progress
  - Galenic formula optimization ongoing
- Preclinical toxicity testing – first part completed
- CRO selected; contract signed
- Clinical centers contacted

ATAC collaborations & pipeline
- Presentation of HER2-ATAC data at AACR
- Encouraging data set for PSMA-ATAC

ATAC Technology Partnerships

- 3 poster presentations: ASH Annual Meeting 2018 (12/2018)
- HDP and Magenta enter into GMP supply agreement for Amanitin linkers
  - In addition to ongoing collaboration
- HDP has secured GMP material capabilities and capacity with Carbogen
  - Positive impact on HDP revenue

Licensed Clinical Projects

- TLX250-CDx
  - New and modernized production process for girentixumab antibody completed
  - Milestone payment to HDP received

- MESUPRON®
  - Link Health received IND approval in China, milestone payment received
HDP-101 – Lead Proprietary ATAC Candidate
Strong Case for Multiple Myeloma

• Amanitin + Linker + BCMA antibody = HDP-101
• Ideal for multiple myeloma (MM) treatment
  • MM remains incurable, median survival of ~30-60 months
  • Current treatments: Chemotherapy, immunomodulatory drugs, proteasome inhibitors and autologous stem cell transplantation
• BCMA expression highly restricted in MM
• Hematological tumor type = good accessibility to tumor cells
• HDP-101 preferential activity against tumor cells with 17p chromosome deletion = potential biomarker
• Additional indications where BCMA expression highly restricted: Diffuse large B-cell lymphoma and chronic lymphocytic leukemia

BCMA ideal target for an ATAC approach, validated through CAR-Ts
# HDP-101 – Current Development Activities

<table>
<thead>
<tr>
<th>Activity</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>GMP technology transfer to the contract manufacturer on an industrial scale</td>
<td>completed</td>
</tr>
<tr>
<td>Production of materials for the HDP-101-toxicology phase</td>
<td>completed</td>
</tr>
<tr>
<td>Preclinical studies with HDP-101-tox material</td>
<td>ongoing</td>
</tr>
<tr>
<td>Longterm stability studies of HDP-101</td>
<td>ongoing</td>
</tr>
<tr>
<td>GMP production of HDP-101 to supply the planned clinical trial</td>
<td>ongoing</td>
</tr>
<tr>
<td>Identification of study centers in GER and the US and establishment of contact</td>
<td>completed</td>
</tr>
<tr>
<td>Outline of the study design for the clinical trial</td>
<td>completed</td>
</tr>
<tr>
<td>Contracts with the study centers</td>
<td>In negotiation</td>
</tr>
<tr>
<td>Submission of the Clinical Trial Application / Investigational New Drug Application for the study and fast track (accelerated process)</td>
<td>In preparation</td>
</tr>
</tbody>
</table>

**Approval of CTA and IND in GER and the US, Initiate study centers and enroll patients**
PSMA-ATAC – Metastatic Castration-Resistant Prostate Cancer (mCRPC)

- PSMA is a clinically validated target, e.g. 177Lu-PSMA-617, a radio-ligand therapy for mCRPC
- PSMA is a commercially attractive target: Novartis acquired Endocyte for that program for USD 2.1 billion
- Strong IP position for the antibody & platform
- Preclinical data package comprises *in vitro* and *in vivo* efficacy, tolerability, PK in rodents and monkeys

- Therapeutic window based on mouse efficacy and monkey tolerability (HNSTD > 7.5 mg/kg) → TI = 15
- Target product profile for metastatic Castration Resistant Prostate Carcinoma (mCRPC)
- Prevalence of 17p del in mCRPC is 63%
- 17p/POLR2A biomarker has been validated preclinically for prostate cancer (Source: Nature Commun. 2018 9:4394)
Triple negative breast cancer (TNBC)

- The surface of the cancer cells has very low levels of binding sites (receptors) for
  1) the hormone estrogen and
  2) the hormone progesterone and the
  3) human epidermal growth factor receptor type 2 (HER2)

- This type occurs in approx. 15 – 20 % of breast cancer patients; often, these tumors are fast-growing and aggressive

- These tumors do not respond to anti-endocrine therapy or treatment with HER2-antibodies

- Significantly worse prognosis compared to other types of breast cancer

- ATAC against the breast cancer antigen HER2

- Particularly effective against aggressive tumors with a 17p deletion

- Dose-dependent tumor regression independent of HER2 expression levels

- Potential effect against tumors with low HER2 expression, such as triple negative breast cancer/TNBC
### Profit and Loss H1 2019

<table>
<thead>
<tr>
<th></th>
<th>H1 2019*</th>
<th>H1 2018*</th>
<th>Change**</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Earnings</strong></td>
<td>4.1</td>
<td>2.2</td>
<td>87%</td>
</tr>
<tr>
<td><strong>Sales revenue</strong></td>
<td>3.8</td>
<td>2.0</td>
<td>88%</td>
</tr>
<tr>
<td><strong>Other income</strong></td>
<td>0.3</td>
<td>0.2</td>
<td>76%</td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td>8.4</td>
<td>6.9</td>
<td>22%</td>
</tr>
<tr>
<td><strong>Cost of sales</strong></td>
<td>1.9</td>
<td>0.8</td>
<td>157%</td>
</tr>
<tr>
<td><strong>R&amp;D costs</strong></td>
<td>5.0</td>
<td>4.6</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Administrative costs</strong></td>
<td>1.4</td>
<td>1.4</td>
<td>1%</td>
</tr>
<tr>
<td><strong>Other expenses</strong></td>
<td>0.1</td>
<td>0.1</td>
<td>-23%</td>
</tr>
<tr>
<td><strong>Net loss for the period</strong></td>
<td>-4.3</td>
<td>-4.7</td>
<td>-8%</td>
</tr>
</tbody>
</table>

* Fiscal year starts December 1st; first half ends May 31st;
** Change based on non-rounded figures

- Significantly higher sales revenue due to ATAC collaborations
- Cost of sales significantly higher due to expanded ATAC technology work and for supplying Amanitin linkers to licensing partners
- R&D slightly higher due to expansion of cost-intensive external GMP production
### Balance Sheet and Cash Flow Statement H1 2019

#### Assets (€ m) 31.05.2019 30.11.2018
- Non-current assets: 11.3 10.9
- Other current assets: 2.6 0.9
- Cash and cash equivalents: 13.1 19.4

#### Equity and Liabilities (€ m) 31.05.2019 30.11.2018
- Current liabilities: 5.4 5.3
- Non-current liabilities: 0.0 0.0
- Equity: 21.6 25.9

#### Cash Flow (€ m) 31.05.2019 31.05.2018
- Cash as of 1 December 2018 / 1 December 2017: 19.4 30.4
- Net change in cash from operating activities: -5.7 -4.1
- Net change in cash from investing activities: -0.6 -0.8
- Net change in cash from financing activities: 0.0 0.0
- Exchange rate effect/Other: 0.0 0.0
- Cash as of 31 May 2019 / 31 May 2018: 13.1 25.5

- Cash and cash equivalents of €13.1 million as of 31 May 2019 (30 November 2018: €19.4 million)
- Average monthly funding requirement was €1.1 million (previous year: €0.8 million)
Heidelberg Pharma Shares

Share performance 2019 ytd

- High: €3.390 (17 April 2019)
- Low: €2.350 (2 January 2019)
- Ave. daily trading volume: 9,095 shares (2018: 34,118)
- Shares outstanding: 28,155,630 (as of 30 June 2019)
- Current market cap: ~€80 m

Analyst coverage

- Pareto 07/19: target €4.10
- EQU.I.TS 03/19: target €5.02
- Baader Helvea 10/18: target €4.40

Share ownership unchanged as of 30 June 2019

- Dietmar Hopp and affiliated companies** 75%
- UCB 4%
- Freefloat 20%
- Corporate bodies * 1%

* held directly
** dievini Hopp BioTech holding GmbH & Co. KG + DH Holding Verwaltungs GmbH
### Financials

<table>
<thead>
<tr>
<th>in € m</th>
<th>FY 2018</th>
<th>6M 2019</th>
<th>Guidance 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue and other income</td>
<td>4.4</td>
<td>4.1</td>
<td>5.0 to 7.0</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>16.0</td>
<td>8.4</td>
<td>14.0 to 18.0</td>
</tr>
<tr>
<td>Operating result (EBIT)</td>
<td>-11.7</td>
<td>-4.3</td>
<td>-8.0 to -12.0</td>
</tr>
<tr>
<td>Funds required</td>
<td>10.9</td>
<td>6.3</td>
<td>10.0 to 14.0</td>
</tr>
<tr>
<td>Funds required per month</td>
<td>0.9</td>
<td>1.1</td>
<td>0.9 to 1.2</td>
</tr>
</tbody>
</table>

- Guidance for 2019 confirmed
- 6M figures in line with guidance, significant increase in sales revenue
- Sufficient funds for operational activities until at least mid-2020 based on current planning
Next Steps and Potential Milestones

ATAC technology and proprietary pipeline

• HDP-101
  • Complete GLP toxicity study
  • Prepare study protocol, sign up study centers
  • Complete GMP manufacturing of clinical trial material
  • Submit Clinical Trial Application in Germany/IND in US for Phase I trial in 2020
  • Initiate clinical development in 2020
  • Continue biomarker development
• Select next proprietary development candidate
• Magenta collaboration
  Generate more preclinical data with C200 (CD117-ATAC), IND submission planned for 2020
• Sign additional license and collaboration agreements with biopharma partners

Partnered legacy clinical programs

REDECTANE® (Telix)
TLX250-CDx – imaging agent
  • ZIRCON Phase III trial: Add new sites in the US and Canada (subject to regulatory approval), complete patient recruitment
TLX250 - 177Lu-girentuximab
  • Initiate combination trials with therapeutic radioimmunoconjugate & checkpoint inhibitor in the US (subject to FDA approval)

MESUPRON® (Link Health)
  • Revise development plan for China based on new NMPA regulations
Investment Summary

Developing new options to address major challenges in cancer therapy

• Heidelberg Pharma is developing new treatment options with Amanitin for different cancer indications, also validated by high quality collaborations

• The innovative first-in-humans mode of action provides high efficacy and potential for unique clinical advantages including treatment of dormant tumor cells as well as increased efficacy against 17p deleted tumor cells

• Value step-up ahead in 2020 as lead product HDP-101 enters the clinic

• Dual business model – early validation and cash through pharma collaborations + future high value potential with proprietary portfolio
## Meet Us

### Upcoming conferences & events

<table>
<thead>
<tr>
<th>Event</th>
<th>Venue</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trout Solebury European Biotech Investor Day 2019</td>
<td>New York</td>
<td>1 August 2019</td>
</tr>
<tr>
<td>Pareto Securities' 10th Annual Health Care Conference</td>
<td>Stockholm</td>
<td>5 September 2019</td>
</tr>
<tr>
<td>Baader Investment Conference</td>
<td>Munich</td>
<td>23 – 26 September 2019</td>
</tr>
<tr>
<td>World ADC Congress</td>
<td>San Diego</td>
<td>8 – 11 October 2019</td>
</tr>
<tr>
<td>European Antibody Congress</td>
<td>Basel</td>
<td>15 – 17 October 2019</td>
</tr>
<tr>
<td>BIO-Europe</td>
<td>Hamburg</td>
<td>11 – 13 November 2019</td>
</tr>
<tr>
<td>PEGS Europe</td>
<td>Lisbon</td>
<td>18 – 22 November 2019</td>
</tr>
<tr>
<td>German Equity Forum</td>
<td>Frankfurt</td>
<td>25 – 27 November 2019</td>
</tr>
<tr>
<td>ASH 2019 Annual Meeting</td>
<td>Orlando</td>
<td>7 – 10 December 2019</td>
</tr>
</tbody>
</table>

### Heidelberg Pharma AG

Schriesheimer Strasse 101  
68526 Ladenburg, Germany  
Tel.: +49 6203 1009-0  
Fax: +49 6203 1009-19  
Website: www.heidelberg-pharma.com

### IR/PR support

MC Services AG  
Katja Arnold (CIRO)  
Tel.: +49 89 210 288-40  
Email: katja.arnold[at]mc-services.eu

### Ticker data

- **ISIN:** DE000A11QVV0  
- **Symbol:** WL6  
- **Reuters:** WL6G.DE  
- **Bloomberg:** WL6.GR
Thank you for your attention